BerandaLSTA • NASDAQ
add
Lisata Therapeutics Inc
Tutup sebelumnya
$2,63
Rentang hari
$2,53 - $2,67
Rentang tahun
$1,87 - $4,20
Kapitalisasi pasar
22,18Â jt USD
Volume Rata-Rata
13,05Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 5,85Â jt | -11,42% |
Laba bersih | -4,72Â jt | 12,53% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,55 | 15,38% |
EBITDA | -5,80Â jt | 11,46% |
Tarif pajak efektif | 16,92% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 25,83Â jt | -40,41% |
Total aset | 28,98Â jt | -39,92% |
Total liabilitas | 3,88Â jt | -29,43% |
Total ekuitas | 25,10 jt | — |
Saham yang beredar | 8,60 jt | — |
Harga terhadap nilai buku | 0,90 | — |
Tingkat pengembalian aset | -45,69% | — |
Tingkat pengembalian modal | -53,50% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -4,72Â jt | 12,53% |
Kas dari operasi | -5,40Â jt | 23,13% |
Kas dari investasi | 9,43Â jt | 46,54% |
Kas dari pembiayaan | -23,00Â rb | 83,80% |
Perubahan kas bersih | 4,01Â jt | 608,63% |
Arus kas bebas | -4,32Â jt | 24,29% |
Tentang
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Didirikan
1980
Kantor pusat
Situs
Karyawan
26
